Navigation Links
Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
Date:2/24/2009

SAN FRANCISCO, Feb. 24 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast of a slide presentation on Wednesday, February 25, at 4:30 p.m. Eastern Time to discuss new efficacy and safety data from the ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer patients.

Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, will participate in the teleconference. He will discuss the new MDV3100 data, as well as recent research regarding the association between changes in the number of circulating tumor cells (CTCs) and the prediction of survival and response to treatment in patients with advanced prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Wednesday, February 25, at 4:30 p.m. Eastern Time by telephone, please dial 877-719-9810 from the U.S. or +1-719-325-4785 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A slide presentation that will accompany the teleconference can be accessed via the Web by accessing the webcast and will also be posted as a PDF next to the event listing in the Investor section of the Medivation website. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
5. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
6. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
7. drugstore.com, inc. to Present at the Upcoming Jefferies 5th Annual Internet & Media Conference
8. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference
9. Case Management Society of America Hosting Conference on Health Care Case Management
10. Service Corporation International Announces Schedule for Its Fourth Quarter 2008 Earnings Release and Conference Call
11. Nationwide to Present at Citigroup Global Property CEO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Virginia Washington, DC (PRWEB) , ... ... ... Media Contact: Claudia Tellez, Executive Director 703.462.0658, ctellez(at)msnva.org , The Medical Society ... for community physicians and their patients , The Medical Society of Northern ...
(Date:5/5/2016)... ... , ... Linfield College Online and Continuing Education is encouraging registered nurses to ... fee for all qualified applicants from May 1–14. Students need only go to the ... . , With the RN to BSN degree program, all core ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... In ... is easy to forget the most important arrangement — planning a safe way of ... celebrations and popular tequila drinks. Unfortunately, these celebrations often lead to drunk drivers on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your ... just a few days away, it’s a good opportunity to raise awareness about a ... American Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ by the ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, the nation’s ... service orders. Blood suppliers and their hospitals use BloodHub for order management, ... active users across 2,100 hospitals who use our platform to processes thousands of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
Breaking Medicine Technology: